GLP-1 agonist · type 2 diabetes
Researchers studying the venom of the Gila monster (Heloderma suspectum) isolated exendin-4, a 39-amino-acid peptide; exenatide is the synthetic version1. It was approved for type 2 diabetes as Byetta in 2005, later joined by the extended-release Bydureon products. Drugs@FDA now lists Byetta's main application, the Bydureon products and an approved generic as discontinued.
GLP-1 is a gut hormone released after meals that prompts the pancreas to release insulin when glucose is high, damps glucagon, slows stomach emptying and reduces appetite. Natural GLP-1 is short-lived because the enzyme DPP-4 breaks it down quickly. Exendin-4 shares about half its sequence with GLP-1 and activates the same receptor, but it resists that breakdown, so its effect lasts much longer1.
In type 2 diabetes this raises insulin release in a glucose-dependent way, lowers inappropriately high glucagon and slows gastric emptying, reducing both fasting and after-meal glucose4. Because the insulin effect depends on glucose, the label flags hypoglycemia mainly when exenatide is combined with sulfonylureas or insulin.
Exendin-4 was found through a systematic search of Gila monster venom; its stability compared with native GLP-1 led to clinical development1. The Byetta label reports human trials of exenatide alone and with metformin, sulfonylureas, thiazolidinediones or insulin glargine; in the 24-week monotherapy trial, HbA1c fell about 0.5 to 0.7 percentage points more than with placebo, alongside modest weight loss4. The EXSCEL outcomes trial followed 14,752 people with type 2 diabetes for a median 3.2 years: extended-release exenatide did not increase major cardiovascular events (hazard ratio 0.91) but did not significantly reduce them, and rates of pancreatitis, pancreatic cancer and medullary thyroid cancer did not differ from placebo2. Exenatide has also been studied in Parkinson's disease; a 96-week phase 3 trial in 194 people found no slowing of motor progression, and the journal later issued an expression of concern about that report3.
The FDA approved Byetta in 2005 and extended-release Bydureon products later to improve glycemic control in type 2 diabetes, with Bydureon BCise also covering children aged 10 and older5. Drugs@FDA lists Byetta's main application (NDA 021773), both Bydureon applications and the Amneal generic as discontinued; a second Byetta application (NDA 021919) is still shown as a prescription product6.
On the Byetta label, the most common reactions were nausea (usually easing over time), hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, indigestion, constipation and weakness. Warnings include acute pancreatitis, kidney injury from dehydration, severe gastrointestinal effects, antibody formation, serious allergic reactions, immune-mediated low platelets with serious bleeding, gallbladder disease and aspiration under anesthesia4. Extended-release forms carry a boxed warning because they caused thyroid C-cell tumors in rats, and are contraindicated with a personal or family history of medullary thyroid cancer or MEN 25.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.